title: Subcutaneous tuberculosis formation during FOLFIRI and bevacizumab treatment: a case report.
authors: Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
authors: Xiao-Wei
authors: XW
authors: Zheng
authors: Department of Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
authors: Li-Li
authors: LL
authors: Ren
authors: Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
authors: Yi-Wen
authors: YW
authors: Zhang
authors: Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
authors: Wen-Juan
authors: WJ
authors: Yin
authors: Emergency Department, Hanggang Hospital, Hangzhou, 310022, Zhejiang, China.
authors: Gang
authors: G
authors: Tao
authors: Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
authors: Wen-Xiu
authors: WX
authors: Xin
authors: Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
authors: Zhong-Jian
authors: ZJ
authors: Chen
authors: Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China. 37751812@qq.com.
authors: Ping
authors: P
authors: Huang
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000068258:Bevacizumab / Q000009:adverse effects*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects; D040521:Subcutaneous Tissue / Q000473:pathology*; D014376:Tuberculosis / Q000139:chemically induced*
chemical_list: D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin